دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Flashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Transitional Cell Carcinoma.
Small, Eric J. MD, FASCO 1,2,,
doi : 10.1200/JCO.23.00286
Volume 41(23) pgs. 3879-3962 August 10, 2023
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.
von der Maase, H.; Hansen, S.W.; Roberts, J.T.; Dogliotti, L.; Oliver, T.; Moore, M.J.; Bodrogi, I.; Albers, P.; Knuth, A.; Lippert, C.M.; Kerbrat, P.; Sanchez Rovira, P.; Wersall, P.; Cleall, S.P.; Roychowdhury, D.F.; Tomlin, I.; Visseren-Grul, C.M.; Conte, P.F.
doi : 10.1200/JCO.22.02763
Systemic Staging of Locally Advanced Breast Cancer: How Hard to Look?.
Pusztai, Lajos MD, DPhil 1,,
doi : 10.1200/JCO.23.00977
Diversifying Eligibility to Enhance Real-World Results.
Fayyaz, Fatima MD 1; Carvajal, Richard D. MD 1,; Devoe, Craig E. MD 1,,
doi : 10.1200/JCO.23.00836
Resection of Residual Masses After Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumors in Adolescents and Adults.
Gilligan, Timothy D. MD 1,
doi : 10.1200/JCO.23.00654
Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for EGFR-Mutated Non-Small-Cell Lung Cancer: Regulatory Considerations.
Goulart, Bernardo H.L. MD, MS 1,; Larkins, Erin MD 1; Beaver, Julia A. MD 1,2,; Singh, Harpreet MD 1,2
doi : 10.1200/JCO.23.00154
Impact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer.
Dayes, Ian S. MD, MSc 1,2,3,4,; Metser, Ur MD 5,6,; Hodgson, Nicole MD, MSc 7; Parpia, Sameer PhD 1,3,4; Eisen, Andrea F. MD 8,9,10,; George, Ralph MD 11,12,; Blanchette, Phillip MD, MSc 13,14; Cil, Tulin D. MD 6,11; Arnaout, Angel MD 15,16; Chan, Adrien MD, MPH 17,18; Levine, Mark N. MD, MSc 1,2,3,4,
doi : 10.1200/JCO.23.00249
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
Dummer, Reinhard MD 1,,; Corrie, Pippa PhD, FRCP 2,; Gutzmer, Ralf MD 3,4,; Meniawy, Tarek M. MD, PhD 5,; Del Vecchio, Michele MD 6,; Lebbe, Celeste MD, PhD 7,; Guida, Michele MD 8,; Dutriaux, Caroline MD 9,; Dreno, Brigitte MD, PhD 10,; Meyer, Nicolas MD, PhD 11,; Ferrucci, Pier Francesco MD 12,; Dalle, Stephane MD, PhD 13,; Khattak, Muhammad Adnan MD 14,15,; Grob, Jean-Jacques MD, PhD 16,; Briscoe, Karen MD 17,; Larkin, James MD, PhD 18,; Mansard, Sandrine MD 19,; Lesimple, Thierry MD, MSc 20,; Guidoboni, Massimo MD 21,; Sabatini, Silvia MD 22; Richtig, Erika MD 23,; Herbst, Rudolf MD 24,; Lobo, Maurice PharmD 25,; Askelson, Margarita MSc 25,; Ascierto, Paolo A. MD 26,; Maio, Michele MD 27,
doi : 10.1200/JCO.22.02199
Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward?.
Tachibana, Isamu MD 1,; Alabd, Andre MD 1; Tong, Yan PhD, MS 2; Piroozi, Alex BS 1; Mahmoud, Mohammad MD 1; Kern, Sean Q. MD 1; Masterson, Timothy A. MD 1; Adra, Nabil MD 3,; Foster, Richard S. MD 1; Hanna, Nasser H. MD 3,; Einhorn, Lawrence H. MD 3; Cary, Clint MD, MPH 1
doi : 10.1200/JCO.22.01822
Management of Residual Nonretroperitoneal Disease in Postchemotherapy Nonseminomatous Germ-Cell Tumors.
King, Jennifer M. MD 1,; Cheng, Michael 2; Kesler, Kenneth MD 3; Ashkar, Ryan MD 1; Althouse, Sandra K. MS 4; Hanna, Nasser H. MD 1,; Einhorn, Lawrence H. MD 1; Adra, Nabil MD 1,
doi : 10.1200/JCO.22.02205
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
Kaiser, Martin F. MD 1,2,,; Hall, Andrew MSc 3; Walker, Katrina MSc 3,; Sherborne, Amy PhD 1; De Tute, Ruth M. PhD 4; Newnham, Nicola BSc 5; Roberts, Sadie PhD 3; Ingleson, Emma PhD 3; Bowles, Kristian PhD 6; Garg, Mamta MD 7,; Lokare, Anand MD 8,; Messiou, Christina MD 1,2,; Houlston, Richard S. MD, PhD 1; Jackson, Graham MD 9,; Cook, Gordon PhD 3,10,; Pratt, Guy MD 5,; Owen, Roger G. MD 4,; Drayson, Mark T. PhD 5,; Brown, Sarah R. PhD 3,; Jenner, Matthew W. MD 11,
doi : 10.1200/JCO.22.02567
Several Questions About Prostate-Specific Antigen and Salvage Radiotherapy After Radical Prostatectomy.
Mai, Zhipeng PhD; Yan, Weigang PhD; Zhou, Yi PhD
doi : 10.1200/JCO.23.00680
Reply to Z. Mai et al.
Tilki, Derya MD; Chen, Ming-Hui PhD; D'Amico, Anthony V. MD, PhD
doi : 10.1200/JCO.23.00845
Genomic Profiling: Can We Rely on Retrospective Analysis to Drive Changes in Clinical Practice?.
Nardone, Valerio MD; Meirson, Tomer MD; De Felice, Francesca MD; Meattini, Icro MD
doi : 10.1200/JCO.23.00334
Reply to V. Nardone et al.
Sjostrom, Martin PhD; Fyles, Anthony MD; Liu, Fei-Fei MD; McCready, David MD; Feng, Felix Y. MD; Speers, Corey W. MD, PhD; Pierce, Lori J. MD; Holmberg, Erik PhD; Ferno, Marten PhD; Malmstrom, Per MD, PhD; Karlsson, Per MD, PhD
doi : 10.1200/JCO.23.00566
Erratum: Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.
doi : 10.1200/JCO.23.00952
Erratum: Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).
doi : 10.1200/JCO.23.01150
Erratum: Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
doi : 10.1200/JCO.23.01230
Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
doi : 10.1200/JCO.23.01239
